Almirall: enters licensing deal for plaque psoriasis cream
(CercleFinance.com) - Spain's Almirall has announced a licensing agreement with Danish biotech firm MC2 Therapeutics, expanding its line of products for the treatment of skin diseases.
Under the deal, MC2 Therapeutics has granted Almirall exclusive European rights to commercialise its Wynzora cream for the treatment of plaque psoriasis.
In exchange, MC2 Therapeutics is eligible to receive upfront payments of 15 million euros prior to launch, in addition to milestone payments on sales and royalties on the European sales
The Wynzora cream received US FDA approval last year, and is currently under review in Europe, supported by two Phase 3 trials.
In 2014 Barcelona-based Almirall initiated a strategic turnaround, aiming to become a leader in dermatology.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Under the deal, MC2 Therapeutics has granted Almirall exclusive European rights to commercialise its Wynzora cream for the treatment of plaque psoriasis.
In exchange, MC2 Therapeutics is eligible to receive upfront payments of 15 million euros prior to launch, in addition to milestone payments on sales and royalties on the European sales
The Wynzora cream received US FDA approval last year, and is currently under review in Europe, supported by two Phase 3 trials.
In 2014 Barcelona-based Almirall initiated a strategic turnaround, aiming to become a leader in dermatology.
Copyright (c) 2021 CercleFinance.com. All rights reserved.